Veradermics, INC

Veradermics, Inc. announced positive topline results from its Phase 2 clinical trial (Study 207) for VDPHL01, an oral extended-release minoxidil formulation, in females with mild-to-moderate pattern hair loss.

Veradermics announced positive Phase 2/3 results for its pattern hair loss treatment VDPHL01, bolstered by a strong cash position from recent financing.

Veradermics, Incorporated has closed a $30 million private placement of pre-funded warrants to institutional investors.

Veradermics, Incorporated announced a preliminary unaudited cash and marketable securities balance of $390.8 million as of March 31, 2026.

Veradermics, Inc. announced positive topline results from its Phase 2/3 clinical trial (Study 302) evaluating VDPHL01 for mild-to-moderate pattern hair loss in males, meeting all primary and key secondary endpoints.

Veradermics reported higher 2025 operating losses, closed a $294.8M upsized IPO in Feb. 2026, completed enrollment in two male Phase 3 trials of VDPHL01, and guided to topline data in 1H and 2H 2026.

Veradermics, Inc. announced positive topline data from its Study 302 evaluating VDPHL01 for pattern hair loss, showing statistically significant improvements in hair count and patient-reported outcomes.

Veradermics, Inc. secures a $30 million investment from Suvretta Capital through a private placement of pre-funded warrants.

Veradermics Director John W. Childs filed an amended Form 4 to correct the nature of indirect beneficial ownership for 294,117 common shares.

Suvretta Capital Management and affiliated funds significantly increased their beneficial ownership in Veradermics, Inc. through open market purchases in early February 2026.

Veradermics, Inc. has filed to increase its initial public offering by approximately $56.8 million, bringing the total potential aggregate offering to over $442 million.

Veradermics, Incorporated has filed a registration statement for a follow-on offering of 3,350,000 shares of common stock or pre-funded warrants to fund commercialization and operations.

Suvretta Capital Management and its affiliates have acquired 300,000 pre-funded warrants in Veradermics, Inc., strengthening their 9.9% stake in the company.

Longitude Capital Partners and associated entities disclosed a 11.3% beneficial ownership stake in Veradermics, Incorporated.

Seven Fleet Master Fund LP has acquired 80,000 shares of Veradermics, Inc., representing a 0.2% ownership stake.

Longitude Capital and its affiliates, including board member Patrick G. Enright, reported a 12.5% beneficial ownership in Veradermics, Incorporated following recent IPO purchases and preferred stock conversions.

Suvretta Capital Management and its affiliated funds have disclosed an 11.9% beneficial ownership stake in Veradermics, Inc., following significant investments including preferred stock conversions, IPO participation, and open market purchases.

SR One Capital Management and affiliated funds have reported a 6.4% beneficial ownership in Veradermics, Inc. following the company's initial public offering and conversion of preferred stock.

Viking Global Investors LP and associated entities filed an amendment to their Schedule 13G, reporting a 4.5% beneficial ownership stake in Veradermics, Inc. following the retirement of David C. Ott.

Citadel entities, including Citadel Advisors LLC and Kenneth Griffin, have reported beneficial ownership of 4.5% of Veradermics, Incorporated's common stock.

Viking Global Investors LP and its affiliates have reported a 5.8% beneficial ownership stake in Veradermics, Inc. following the company's recent initial public offering.